Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ne47 Bio Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are reviewed by 2 distinct examiners but are located within 1 distinct art unit, indicating a concentration of technical subject matter.
The busiest examiner for the company is KRIANGCHAIVECH, KETTIP, who is handling 1 pending office action. Since there are 2 pending office actions in total, the workload is split between the 2 distinct examiners. The fact that both examiners are within 1 distinct art unit suggests that while different individuals are reviewing the applications, the company's current biotechnology filings fall under the same technical classification. This allows the company to focus on the specific standards of 1 distinct art unit while managing 2 separate examiner relationships. For a practitioner, the concentration of 2 pending actions in 1 distinct art unit simplifies the technical landscape even with 2 distinct examiners involved in the review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRIANGCHAIVECH, KETTIP | 1 | 19.0% | +28.8% |
| NEGIN, RUSSELL SCOTT | 1 | 55.9% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443534 | Protein engineering workflow using a generative model of protein families | KRIANGCHAIVECH, KETTIP | — |
| 18084757 | Protein database search using learned representations | NEGIN, RUSSELL SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443534 | Protein engineering workflow using a generative model of protein families | KRIANGCHAIVECH, KETTIP | — |
| 18084757 | Protein database search using learned representations | NEGIN, RUSSELL SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443534 | Protein engineering workflow using a generative model of protein families | KRIANGCHAIVECH, KETTIP | 1686 | §101§103§112 | Final Rejection | — | Pending | Feb 16, 2024 |
| 18084757 | Protein database search using learned representations | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Final Rejection | — | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNe47 Bio Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Kettip Kriangchaivech has the most, with 1 of Ne47 Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
